Saturday 17 October 2026
Export DARE’s income statement to Excel — free account
Dare Bioscience, Inc.
DARE Healthcare Biotechnology
Dare Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, up 10,412.2% from fiscal 2024. In the quarter to June 2026, revenue grew 984.4%, EPS grew 55.6% and free cash flow fell 30.2%, each against the same quarter a year earlier.
0.72
0.02
−2.70%
Follow DARE
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | — | 4 | 4 |
P/E ratio |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(66.75) | — | — | — | — | — | (5.04) | (15.48) | (14.21) | (8.92) |
P/S ratio |
0.00 | — | — | — | — | — | 0.00 | 2.24 | 2,705.33 | 20.94 |
P/FCF ratio |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 5.41 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(253.72) | — | — | — | — | — | (13.24) | (37.11) | (34.15) | (20.96) |
P/Operating CF |
(38.51) | — | — | — | — | — | (12.45) | (3.51) | 5.00 | 14.94 |
Beneish M-Score |
— | — | — | — | — | — | — | 2.69 | 20.76 | — |
P/B ratio |
0.00 | — | — | — | — | — | 6.61 | 0.00 | 0.00 | 7.59 |
Price to Tangible BV |
0.00 | — | — | — | — | — | 12.39 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | — | — | — | — | — | 0.00 | 2.06 | 1,941.77 | 5.07 |
EV/EBITDA |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(56.75) | — | — | — | — | — | (2.60) | (0.68) | 3.48 | (0.53) |
EV/FCF |
(21.31) | — | — | — | — | — | (2.59) | (0.67) | 3.88 | (0.51) |
Quick Ratio |
0.06 | 8.11 | 6.27 | 0.95 | 0.67 | 3.29 | 1.15 | 0.56 | 0.74 | 1.04 |
Current Ratio |
0.06 | 8.64 | 6.64 | 1.15 | 0.91 | 3.44 | 1.36 | 0.86 | 0.85 | 1.14 |
Net Debt/EBITDA |
0.07 | 2.05 | 0.58 | 0.33 | 0.17 | 1.32 | 1.11 | 0.34 | 0.67 | 2.07 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.20 | 0.09 | 0.00 | 0.04 |
Operating CF/Net income |
0.55 | 0.22 | 0.61 | 0.88 | 0.92 | 0.74 | 0.58 | 1.29 | (1.35) | 0.74 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | (0.41) | (0.55) | (2.61) | (16.39) | (13.55) | (0.24) |
Interest Coverage |
(14.98) | — | — | — | — | — | — | — | — | — |
| (2.80%) | (182.85%) | (167.23%) | (420.05%) | 7,710.68% | (205.82%) | (124.12%) | (994.69%) | 73.30% | 845.52% | |
| (1.72%) | (160.83%) | (151.57%) | (197.16%) | (365.59%) | (122.15%) | (62.12%) | (92.65%) | (18.69%) | (49.10%) | |
ROIC |
0.00% | (121.89%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
1,579.11% | (155.82%) | (271.81%) | (1,681.94%) | 4,290.48% | (98.54%) | (269.58%) | 1,322.35% | 221.57% | (271.40%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 62.17 | 123.39 | 8,566.33 | 0.00 |
Research and Development Expense of Revenue |
9.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 300.42% | 767.05% | 145,971.43% | 536.15% |
Selling, General and Administrative Expense of Revenue |
72.83% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 113.43% | 434.83% | 93,429.59% | 850.65% |
Intangible Assets out of Total Assets |
0.00 | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 21.59% | 90.13% | 22,482.65% | 145.27% |
Graham Net Nets |
(0.11) | — | — | — | — | — | 0.14 | (0.31) | (0.36) | (0.12) |
Graham Number |
46.61 | — | — | — | — | — | 0.00 | 7.98 | 2.82 | 0.00 |
Earnings Yield |
(10.23%) | — | — | — | — | — | (42.06%) | (103.33%) | (16.04%) | (64.77%) |
Free Cash Flow Yield |
(15.41%) | — | — | — | — | — | (24.73%) | (137.60%) | 18.48% | (47.61%) |
Revenue per Share |
11.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42 | 0.39 | 0.00 | 0.09 |
Operating CF per Share |
(5.35) | (9.44) | (11.49) | (10.26) | (10.07) | (5.65) | (2.57) | (5.34) | 0.64 | (0.88) |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | (0.01) | 0.00 | (0.01) | (0.09) | (0.07) | (0.03) |
Free Cash Flow per Share |
(5.35) | (9.44) | (11.50) | (10.26) | (10.07) | (5.65) | (2.58) | (5.43) | 0.58 | (0.92) |
Cash per Share |
0.64 | 28.08 | 7.61 | 3.68 | 1.86 | 10.14 | 4.92 | 1.44 | 1.85 | 2.21 |
Shareholders Equity per Share |
(10.21) | 49.38 | 7.52 | 0.34 | (0.46) | 7.61 | 1.58 | (0.69) | (0.71) | 0.25 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(10.21) | 49.38 | 7.52 | 0.34 | (0.46) | 7.61 | 1.58 | (0.69) | (0.71) | 0.25 |
Free Cash Flow |
(0.37) | (2.54) | (10.28) | (13.32) | (25.25) | (28.78) | (18.15) | (39.49) | 4.90 | (10.27) |
Working Capital |
(0.71) | 7.38 | 6.15 | 0.83 | (0.68) | 39.24 | 11.41 | (2.94) | (3.17) | 3.38 |
Capital Expenditures |
(0.53) | — | (0.01) | — | (0.02) | (0.01) | (0.06) | (0.63) | (0.57) | (0.39) |
Net Current Asset Value |
(0.71) | 7.38 | 6.14 | (0.56) | (1.72) | 38.24 | 10.32 | (8.79) | (9.67) | (2.57) |
EV/EBIT |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.01 | 0.22 | 58.47 | 0.37 |
Price to Operating Income |
0.00 | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.39 | 0.00 | 552.13 | 0.17 | 1.14 | 1.02 | 0.37 | 0.06 | 0.03 | 1.05 |
Cash ROIC |
55.90% | (12.18%) | (75.97%) | (255.04%) | (717.85%) | (31.82%) | (39.65%) | (727.39%) | 50.59% | (37.28%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.02 | 2.12 | 0.02 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.01 | 0.01 | 0.04 | 0.02 | 0.02 | 0.00 | 0.00 | 0.22 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 69,912.71 | 35,618.74 | 8,629.04 | 29,076.95 | 15,550.84 | 0.00 | 0.00 | 1,481.59 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Average Receivables |
— | 0.84 | 0.16 | 0.29 | 0.51 | 0.80 | 1.42 | 1.33 | 0.59 | — |
Average Payables |
1.12 | 0.16 | 0.38 | 0.77 | 1.05 | 1.56 | 2.07 | 2.71 | 2.42 | 1.33 |
Average Assets |
39.13 | 7.15 | 11.04 | 7.64 | 7.50 | 31.68 | 49.82 | 32.55 | 21.69 | 27.29 |
Average Common Equity |
24.02 | 6.29 | 10.01 | 3.58 | (0.36) | 18.80 | 24.93 | 3.03 | (5.53) | (1.58) |
Columns are period end dates